Hangzhou Celregen Therapeutics

Hangzhou Celregen Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation cell therapies for regenerative medicine and immune-related diseases. Founded in 2021 and headquartered in Hangzhou, China, the company utilizes proprietary induced pluripotent stem cell (iPSC) and mesenchymal stem cell (MSC) platforms to create standardized, "off-the-shelf" therapeutic products. Its lead candidate, CR-001, is an umbilical cord-derived MSC therapy currently in clinical trials for the treatment of acute-on-chronic liver failure. Celregen also advances a pipeline of iPSC-derived cells, including iMSCs and iNK cells, targeting orthopedic conditions and oncology. The company aims to address significant unmet medical needs by providing scalable and high-quality cell-based solutions.